Which sub populations are more at-risk for cognitive decline and fast disease progression?
The Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease (AD) is a unique translational project aimed at characterizing a finite set of therapeutically relevant AD subtypes taking into account known genetic factors, biologic “endophenotypes” assessed by blood, cerebrospinal fluid (CSF), or brain imaging, as well as aspects of clinical phenotype.
The ultimate goal is to translate this knowledge into clinical care by defining patients who respond optimally to currently available and emerging therapies. Subtyping will also lead to identifying new therapeutic targets based on refined and granular understanding of disease mechanisms.
Alzheimer's and Dementia Research
Questions we're asking that inform us on how to best care for patients include:
Big Data Power
Scaling Evidenced-Based Care
How can the current quality care be made available to all persons with dementia throughout Johns Hopkins?
Closing the Loop
How can we fast track the research from clinic to test tube and back to the clinic with biomarkers for subtyping and for advancing therapeutics?
Innovation - Brain Scans
How can existing brain MRI methods be refined for early detection, prognosis, or predicting response to available medications?
Innovation - New Blood Test
Can novel blood tests based on “exosomes” be used to learn about what’s going on in the brain so as to stage the AD brain disease and monitor treatment response?
Innovation - Stem Cell Models
Can blood derived stems cells be used to test whether individual patients will be helped by available and emerging medication treatments?
Patient Care for Alzheimer's Disease
The research we do directly impacts the treatment options available to our patients. Find out more about patient care for Alzheimer's Disease.
The Johns Hopkins Memory and Alzheimer's Treatment Center
The Johns Hopkins Bayview Medical Center
5300 Alpha Commons Drive, Floor 4
Baltimore, MD 21224
Dimitrios Kapogiannis, M.D. is Chief of the Human Neuroscience Unit at the National Institute of Aging and adjunct Associate Professor in the Department of Neurology at Johns Hopkins. He is a clinician-scientist, ABPN-certified in Neurology and UCNS-certified in Behavioral Neurology. His translational laboratory focuses on discovering novel biomarkers for preclinical diagnosis and therapeutic response in Alzheimer's and other neurodegenerative diseases. He has pioneered deriving Extracellular Vesicles enriched for neuronal and astrocytic origin from peripheral blood.